Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis
Top Cited Papers
- 1 September 2011
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 24 (9) , 1248-1253
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53)Deletion in Chronic Lymphocytic LeukemiaAmerican Journal of Clinical Pathology, 2010
- Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancersGynecologic Oncology, 2008
- The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant TreatmentJournal of Clinical Oncology, 2005
- The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder CancerJournal of Urology, 2003
- A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumorsCancer, 2003
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJournal of Clinical Investigation, 1999
- Molecular analysis of different allelic variants of wild-type human p53Biochemistry and Cell Biology, 1992
- Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformationExperimental Cell Research, 1991
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989